Long-Term Outcome Analysis of Isatuximab-Based Triplet

(MedPage Today) -- The phase III IKEMA study investigated the anti-CD38 monoclonal antibody isatuximab plus carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma previously treated with one to three lines of therapy...